POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 2023-06, Vol.41 (S2), p.615-615
Hauptverfasser:	Cliff, E. R. S., Rand, L. Z., Hogervorst, M. A., Feldman, W. B., Kesselheim, A. S., Raymakers, A. J. N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Comparative analysis Monoclonal antibodies Technology assessment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	615
container_issue	S2
container_start_page	615
container_title	Hematological oncology
container_volume	41
creator	Cliff, E. R. S. Rand, L. Z. Hogervorst, M. A. Feldman, W. B. Kesselheim, A. S. Raymakers, A. J. N.
description
doi_str_mv	10.1002/hon.3165_463
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3089979011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089979011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1495-62ae17f92ab84c71f36c6bafd9a01e78607425bf65aa613fa9672bd3ec158b893</originalsourceid><addsrcrecordid>eNp9kNFKwzAYhYMoOKd3PkDAmwlWk2ZNG-9il62Fri1NO5k3Ie1aVHSbrUO88wnEZ_RJzJjeenX4-b9zDhwATjG6xAjZV_er5SXB1FFDSvZADyPGLIwo2wc9ZLuehWxiH4KjrntEyPyQ1wOfaRLxvLgrpvwG8ngE80DANEsmmZAyTOLvj69xJgSURTYLZzyCg3Qszw0hRqHPpyLOryGHfjJNecbzcCZMCI_mMpQwGcNA8CgPYC78IE6iZDKHXEoTvPVBPhGxP4eDIOfnMBOzUNzKY3DQ6KeuPvnVPijGIvcDy5hNX2RVeMgci9q6xm7DbF16w8rFDaEVLXWzYBrh2vUocoe2UzbU0Zpi0mhGXbtckLrCjld6jPTB2S533a5eNnX3qh5Xm3ZpKhVBHmMuQxgb6mJHVe2q69q6Uev24Vm37wojtV1cmcXV3-IGd3b428NT_f4vq4Ik3sr2Jj-5PHng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089979011</pqid></control><display><type>article</type><title>POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS</title><source>Wiley Online Library All Journals</source><creator>Cliff, E. R. S. ; Rand, L. Z. ; Hogervorst, M. A. ; Feldman, W. B. ; Kesselheim, A. S. ; Raymakers, A. J. N.</creator><creatorcontrib>Cliff, E. R. S. ; Rand, L. Z. ; Hogervorst, M. A. ; Feldman, W. B. ; Kesselheim, A. S. ; Raymakers, A. J. N.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3165_463</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Comparative analysis ; Monoclonal antibodies ; Technology assessment</subject><ispartof>Hematological oncology, 2023-06, Vol.41 (S2), p.615-615</ispartof><rights>2023 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.3165_463$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.3165_463$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids></links><search><creatorcontrib>Cliff, E. R. S.</creatorcontrib><creatorcontrib>Rand, L. Z.</creatorcontrib><creatorcontrib>Hogervorst, M. A.</creatorcontrib><creatorcontrib>Feldman, W. B.</creatorcontrib><creatorcontrib>Kesselheim, A. S.</creatorcontrib><creatorcontrib>Raymakers, A. J. N.</creatorcontrib><title>POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS</title><title>Hematological oncology</title><subject>Comparative analysis</subject><subject>Monoclonal antibodies</subject><subject>Technology assessment</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kNFKwzAYhYMoOKd3PkDAmwlWk2ZNG-9il62Fri1NO5k3Ie1aVHSbrUO88wnEZ_RJzJjeenX4-b9zDhwATjG6xAjZV_er5SXB1FFDSvZADyPGLIwo2wc9ZLuehWxiH4KjrntEyPyQ1wOfaRLxvLgrpvwG8ngE80DANEsmmZAyTOLvj69xJgSURTYLZzyCg3Qszw0hRqHPpyLOryGHfjJNecbzcCZMCI_mMpQwGcNA8CgPYC78IE6iZDKHXEoTvPVBPhGxP4eDIOfnMBOzUNzKY3DQ6KeuPvnVPijGIvcDy5hNX2RVeMgci9q6xm7DbF16w8rFDaEVLXWzYBrh2vUocoe2UzbU0Zpi0mhGXbtckLrCjld6jPTB2S533a5eNnX3qh5Xm3ZpKhVBHmMuQxgb6mJHVe2q69q6Uev24Vm37wojtV1cmcXV3-IGd3b428NT_f4vq4Ik3sr2Jj-5PHng</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Cliff, E. R. S.</creator><creator>Rand, L. Z.</creator><creator>Hogervorst, M. A.</creator><creator>Feldman, W. B.</creator><creator>Kesselheim, A. S.</creator><creator>Raymakers, A. J. N.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202306</creationdate><title>POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS</title><author>Cliff, E. R. S. ; Rand, L. Z. ; Hogervorst, M. A. ; Feldman, W. B. ; Kesselheim, A. S. ; Raymakers, A. J. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1495-62ae17f92ab84c71f36c6bafd9a01e78607425bf65aa613fa9672bd3ec158b893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Comparative analysis</topic><topic>Monoclonal antibodies</topic><topic>Technology assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cliff, E. R. S.</creatorcontrib><creatorcontrib>Rand, L. Z.</creatorcontrib><creatorcontrib>Hogervorst, M. A.</creatorcontrib><creatorcontrib>Feldman, W. B.</creatorcontrib><creatorcontrib>Kesselheim, A. S.</creatorcontrib><creatorcontrib>Raymakers, A. J. N.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cliff, E. R. S.</au><au>Rand, L. Z.</au><au>Hogervorst, M. A.</au><au>Feldman, W. B.</au><au>Kesselheim, A. S.</au><au>Raymakers, A. J. N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS</atitle><jtitle>Hematological oncology</jtitle><date>2023-06</date><risdate>2023</risdate><volume>41</volume><issue>S2</issue><spage>615</spage><epage>615</epage><pages>615-615</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.3165_463</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0278-0232
ispartof	Hematological oncology, 2023-06, Vol.41 (S2), p.615-615
issn	0278-0232 1099-1069
language	eng
recordid	cdi_proquest_journals_3089979011
source	Wiley Online Library All Journals
subjects	Comparative analysis Monoclonal antibodies Technology assessment
title	POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A17%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=POLATUZUMAB%20AND%20THE%20PROGRESSION%E2%80%90FREE%20SURVIVAL%20(PFS)%20PREDICAMENT:%20A%20COMPARATIVE%20ANALYSIS%20OF%20HEALTH%20TECHNOLOGY%20ASSESSMENT%20AGENCY%20(HTA)%20REVIEWS&rft.jtitle=Hematological%20oncology&rft.au=Cliff,%20E.%20R.%20S.&rft.date=2023-06&rft.volume=41&rft.issue=S2&rft.spage=615&rft.epage=615&rft.pages=615-615&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3165_463&rft_dat=%3Cproquest_cross%3E3089979011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089979011&rft_id=info:pmid/&rfr_iscdi=true